CCR1 and CCR5 are therapeutic targets for autoimmune diseases (O’Hayre et al. 2010; Proudfoot et al. 2010), multiple sclerosis (MS) and rheumatoid arthritis. Here, CCR1 is linked to myeloid sarcoma.